UNSPSC 51142317: Naltrexone hydrochloride

This classification denotes an opiate antagonist with the molecular formula C20H23NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z6375YW9SF, chemically known as 17-(cyclopropylmethyl)-4,5-alpha-epoxy-3,14-dihydroxy-morphinan-6-one hydrochloride but more generally known as naltrexone hydrochloride, which bears US NIH Compound Identifier 5485201. European Medicines Agency schedules Naltrexone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14629MIG.

UNSPSC 51142317 Naltrexone hydrochloride is a Commodity code that describes a specific pharmaceutical product — an opioid antagonist medication — procured by state and local health agencies, primarily for overdose-reversal and substance-use disorder treatment programs. Recent state and local solicitations show purchasing bodies acquiring naltrexone as part of broader public-health initiatives, including opioid-response programs, community health services, and multi-drug pharmacy benefit contracts. The issuing bodies span county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple state and local jurisdictions. Work under this code includes both direct procurement of naltrexone units for distribution to community health sites and enrollment of naltrexone in larger pharmaceutical supply contracts managed through authorized wholesalers and pharmacy benefit programs.

Activity appears concentrated in Florida and Texas, with multi-state cooperative purchasing vehicles adding breadth across additional jurisdictions. Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026 seeking 1,900 units of naloxone and related deactivation systems annually with quarterly deliveries, due July 26, 2023 — a response date already passed. The Texas Health and Human Services Commission issued a Request for Information (HHS0017013) in April 2026 exploring direct-to-manufacturer pharmacy programs that would include prescription fulfillment for state employees and health plans. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP (S1070000015802) on January 20, 2026 with a March 26, 2026 deadline for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, including Oregon. Vendors responding to MMCAP contracts must maintain relationships with authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, comply with cGMP and Drug Supply Chain Security Act requirements, and accept a 3 percent administrative fee.